IMR Press / EJGO / Volume 30 / Issue 3 / pii/2009071

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research

ERBB2 (HER2) protein expression in uterine sarcomas

Show Less
1 1st Department of Obstetrics & Gynecology, Aristotle University of Thessaloniki, Papageorgiou General Hospital (Greece)
2 Department of Pathology, Hippokrateio General Hospital, Thessaloniki (Greece)
Eur. J. Gynaecol. Oncol. 2009, 30(3), 292–294;
Published: 10 June 2009
Abstract

Purpose: Multiple clinical trials in recent years have shown that breast cancer patients with primary tumors overexpressing ERBB2 can be effectively treated with specific forms of modern anti-ERBB2-targeted therapy. The aim of the present study was to analyze the expression of the ERBB2 (HER2) protein in uterine sarcomas, in order to investigate the possibility of applying this treatment modality in uterine sarcomas. Methods: The expression of ERBB2 has been analyzed immunohistochemically in forma-lin-fixed paraffin-embedded primary uterine sarcomas (n = 11). Results: Using a semi-quantitative immunohistochemical score, we found that ERBB2 expression was very weak in the majority of tumors, with only three sarcomas showing moderate ERBB2 expression. Published studies evaluating the same issue in small numbers of uterine sarcomas reached similar findings. Conclusion: Overall, ERBB2 expression appears to be weak in uterine sarcomas. However, targeted treatment might still be feasible in a subgroup of patients with uterine sarcomas overexpressing ERBB2.

Keywords
Uterine sarcoma
ERBB2
HER2
Targeted therapy
Trastuzumab
Herceptin®
Lapatinib
Tykerb®
Share
Back to top